Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors by Thomas R. Kreil

Get full text

Development of a Triton X‐100 replacement for effective virus inactivation in biotechnology processes by Jean‐Baptiste Farcet, Johanna Kindermann, Michael Karbiener, Thomas R. Kreil

Get full text

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize by Maria R. Farcet, Julia Schwaiger, Michael Karbiener, Thomas R. Kreil

Get full text

West Nile Virus Infection in Plasma of Blood and Plasma Donors, United States by Christina B. Planitzer, Jens Modrof, Mei-ying W. Yu, Thomas R. Kreil

Get full text

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines by Michael Karbiener, Maria R. Farcet, Andreas Zollner, Taisei Masuda, Mitsuhiro Mori, Alexander R. Moschen, Thomas R. Kreil

Get full text

Sample Buffer Containing Guanidine-Hydrochloride Combines Biological Safety and RNA Preservation for SARS-CoV-2 Molecular Diagnostics by Lisa Weidner, Sandra Laner-Plamberger, David Horner, Charlotte Pistorius, Jennifer Jurkin, Michael Karbiener, Elisabeth Schistal, Thomas R. Kreil, Christof Jungbauer

Get full text

H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. by M Keith Howard, Nicolas Sabarth, Helga Savidis-Dacho, Daniel Portsmouth, Otfried Kistner, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett

Get full text

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. by Annett Hessel, Helga Savidis-Dacho, Sogue Coulibaly, Daniel Portsmouth, Thomas R Kreil, Brian A Crowe, Michael G Schwendinger, Andreas Pilz, P Noel Barrett, Falko G Falkner, Birgit Schäfer

Get full text

Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2 by Laxmikant Wali, Michael Karbiener, Scharon Chou, Vitalii Kovtunyk, Adam Adonyi, Irene Gösler, Ximena Contreras, Delyana Stoeva, Dieter Blaas, Johannes Stöckl, Thomas R. Kreil, Guido A. Gualdoni, Anna-Dorothea Gorki

Get full text

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. by Annett Hessel, Michael Schwendinger, Georg W Holzer, Klaus K Orlinger, Sogue Coulibaly, Helga Savidis-Dacho, Marie-Luise Zips, Brian A Crowe, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett, Falko G Falkner

Get full text

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations. by Annett Hessel, Michael Schwendinger, Daniela Fritz, Sogue Coulibaly, Georg W Holzer, Nicolas Sabarth, Otfried Kistner, Walter Wodal, Astrid Kerschbaum, Helga Savidis-Dacho, Brian A Crowe, Thomas R Kreil, P Noel Barrett, Falko G Falkner

Get full text

B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19 by Andreas Zollner, Christina Watschinger, Annika Rössler, Maria R. Farcet, Agnes Penner, Vincent Böhm, Sophia J. Kiechl, Gerald Stampfel, Rainer Hintenberger, Herbert Tilg, Robert Koch, Marlies Antlanger, Thomas R. Kreil, Janine Kimpel, Alexander R. Moschen

Get full text

A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. by Otfried Kistner, Brian A Crowe, Walter Wodal, Astrid Kerschbaum, Helga Savidis-Dacho, Nicolas Sabarth, Falko G Falkner, Ines Mayerhofer, Wolfgang Mundt, Manfred Reiter, Leopold Grillberger, Christa Tauer, Michael Graninger, Alois Sachslehner, Michael Schwendinger, Peter Brühl, Thomas R Kreil, Hartmut J Ehrlich, P Noel Barrett

Get full text